The PREVAiLS study, believed to be the only recruiting phase 3 ALS trial, aims to slow disease progression and preserve ...

One ALS patient received TRE-515 under the FDA program last year, and early signs suggest the therapy may help stabilize ...

The new project combines clinical data with advanced analytics and artificial intelligence in an effort to create ...

ALS is life‑changing, but new treatments, specialized care, and innovative research are bringing real hope. See how advances at University of Utah Health are shaping the future of ALS care.

NAARDEN, The Netherlands & WALTHAM, Mass. & BARCELONA, Spain, March 30, 2026--Prilenia Therapeutics B.V. and Ferrerii today announced the first enrollment in the pivotal, 500-participant, randomized, ...

IV edaravone-treated patient had longer disease progression milestone-free time for all 6 milestones compared with control. Treatment with intravenous (IV) edaravone was associated with fewer reported ...

Please provide your email address to receive an email when new articles are posted on . A new analysis of an overall survival study of an investigational immunotherapy platform to treat ALS found it ...

Amyotrophic lateral sclerosis remains difficult to diagnose and is frequently identified after substantial disease progression, underscoring the need for earlier recognition and expanded therapeutic ...

In early February, Congress passed a budget that included $315 million for ALS research, the most funding ever for ALS. But ...

Shelly Stellato, 37, and Mira Hudson, 29, are part of a largely unseen group: young women with neurodegenerative disease ALS.